Dr. Kent Brantly's release came two days after a second U.S. missionary, Nancy Writebol, was quietly allowed to leave Emory University Hospital.» Read More
Instead of criticizing foreign deals, we should be talking about corporate-tax reform to bring business—and jobs—back to the US, says Jake Novak.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
AstraZeneca shares fall 13 percent after it rejects a final bid from Pfizer, calling the offer inadequate and presenting significant risks.
Ahead of the year's biggest event in cancer research, ASCO, research revealed AstraZeneca's cancer drug may have competition from Clovis Oncology.
The war of words over Pfizer’s attempts to take over AstraZeneca has escalated, with one politician invoking rape to describe the U.S. giant’s bids.
Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.
U.K. hearings over a potential AstraZeneca-Pfizer tie-up was a chance to discuss "Entente Cordiale" and whether leopards will change their spots.
CNBC's Meg Tirrell reports both Pfizer and AstraZeneca CEOs are facing tough questions by the UK Parliament on the possible merger.
The CEO of AstraZeneca told CNBC the U.K. pharmaceutical giant was big enough to thrive alone, but would still consider a takeover bid.
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Pfizer kicked off the most important week to date in its struggle to gain control of U.K. rival AstraZeneca.
Allergan is set to reject a $46bn offer by rival Valeant Pharmaceutical, a move likely to spur a takeover battle in the US drug-making industry. FT.
It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.
May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments.
AstraZeneca, the pharmaceutical company fighting off repeated approaches from larger rival Pfizer, has boosted its defense against the raid.
The FDA said that people should use daily aspirin therapy only after assessing the benefits and risks.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
Get the best of CNBC in your inbox